Peter Evan Harwin - 09 Jun 2026 Form 4 Insider Report for Cogent Biosciences, Inc. (COGT)

Source evidence Original filing metadata and source links for verification. 4 source fields
SEC form
4
Accepted by SEC
11 Jun 2026, 16:30:27 UTC
Prior SEC filing
05 Jun 2025
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Evan D. Kearns, Attorney-in-Fact

Key filing fact

Peter Evan Harwin filed Form 4 for Cogent Biosciences, Inc. (COGT) on 11 Jun 2026.

Key facts

  • This page summarizes Peter Evan Harwin's Form 4 filing for Cogent Biosciences, Inc. (COGT).
  • 1 reported transaction and 1 derivative row are listed below.
  • Accepted by SEC: 11 Jun 2026, 16:30.

Change

  • Previous filing in this sequence was filed on 05 Jun 2025.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001663607 Primary reporting owner

Harwin Peter Evan

Relationship
Director
Address
C/O COGENT BIOSCIENCES, INC., 180 THIRD AVENUE, 4TH FLOOR, WALTHAM
Signature
/s/ Evan D. Kearns, Attorney-in-Fact
Signature date
11 Jun 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

COGT transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares
+17,901
Change %
Price
$0.000000*
Shares after
17,901
Date
09 Jun 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
17,901
Exercise price
$31.98
Footnotes
F1, F2
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

This stock option shall vest in full upon the earlier of the first anniversary of the date of grant or the date of the 2027 Annual Meeting of Stockholders, subject to the Reporting Person's continued service to the Issuer through such date.

Footnote F2

Under the Reporting Person's arrangement with Fairmount Funds Management LLC (the "Adviser"), the Reporting Person holds the option for one or more investment vehicles managed by the Adviser (each, a "Fairmount Fund"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received from the option for the benefit of such Fairmount Fund. The Reporting Person therefore disclaims beneficial ownership of the option and underlying common stock.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .